Mgmt get$ paid big $! sales reps, not so much

Discussion in 'Vivus Pharmaceuticals' started by Anonymous, Jun 7, 2013 at 7:44 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Vivus is paying 15 million a quarter to PDI. With about 200 reps that is about 75K/rep. They may not be getting "rich" but given the recent results it sure looks like Vivus is the one paying to much. Can't say I agree with "they are worth what they are being paid"- 3 something scripts per week is hardly acceptable by any standard.
     

  2. Anonymous

    Anonymous Guest

    There is a lot that goes into ypue assumption here. Your 3 script average was severely impacted by a flawed home delivery system that took up to 8 weeks to process each prescription instead of the 5-7 days that was promised. Pricing for qsymia was developed looking at the cash products that patients still pay $80-$200 a month for without blinking, but because qsymia is a prescription medication joe public cries if there is anything more than a $20 copay. Lastly, I wish there were 200 of us. Try about 35-50 less. We can't get to everbody that wants to talk to us.... Qsymia is now easier to get, insurance coverage is geeting better, and the 3's are turning to 23's and they will turn to 103's keep watching. Yes-i am one of those reps and even under the old conditions i was doing betternthan your assumptions. If you think you are so good come on out and try big guy.
     
  3. Anonymous

    Anonymous Guest

    Come out and try it big guy????? Listen, with all of the pouting going on with this board it is the investors that have dealt with nearly a 1/2 billion dollars in looses since this company was founded. With out the continious offering of stock by the company over the years and the investment of capital by individual investors this company would be nowhere and the reps on this site maybe jobless.
    No question, there have been obstacles partly created by an incompetent leader who is no longer there but when the chips are down you need to push yourself. Regardless of what you think about large organizations, good people tend to be noticed. If a BP were to come into play my guess would be that the top PDI people would be offered positions. It only makes sense. You keep the best and let the others go.
    The bottom line, the company needs to drive sales and more of it for things to continue. The ridiculous executive pay structure is in the past. For Vivus to become successful the reps need to expect more from themselves- Qsymia won't sell itself.
     
  4. Anonymous

    Anonymous Guest

    Amen. I have no problem with that. There are issues those very dollars that went other places could have addressed and qsymia would not have had to face the issues ut did during the initial launch. The same can be said today, but i do believe the new team is trying to change this. Hey, i am one of the few. I have other places to go but i believe in this drug and like the people who have adopted it. I m staying a little while longer to see and always push myself. The problems my friend are still behind the scenes. Dont always point at the face of the issue. Look behind the mask.
     
  5. Anonymous

    Anonymous Guest

    $9 co-pay for VA - do patients get qsymia in-house or in retail?
     
  6. Anonymous

    Anonymous Guest

    through express scripts (ESI) mail only -